NCT06390709View on ClinicalTrials.gov

PREDICT Therapy Selection for JAK, T-cell, or IL-6 Inhibitor Therapies Using a Molecular Signature Response Classifier (PREDICT)

RecruitingOBSERVATIONAL

Enrollment

1,100

Participants

Timeline

Start Date

April 8, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions

Rheumatoid Arthritis

Interventions

OTHER

Lab Collection Only

2 Paxgene and 1 SST tubes will be collected at 2 timepoints throughout the study.

Trial Locations (1)

90602

RECRUITING

Medvin Clinical Research//Amicus Arthritis, Whittier

Sponsors

Lead Sponsor

Scipher Medicine

All Listed Sponsors

lead

Scipher Medicine

INDUSTRY

NCT06390709 - PREDICT Therapy Selection for JAK, T-cell, or IL-6 Inhibitor Therapies Using a Molecular Signature Response Classifier (PREDICT) | Biotech Hunter | Biotech Hunter